You are here: Industry Insights > Kazia

News List

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma prnasia
December 06, 2021
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy...
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day Kazia
July 22, 2021
Kazia Therapeutics Limited yesterday recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs prnasia
July 01, 2021
Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma prnasia
June 16, 2021
Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II ...
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient prnasia
June 08, 2021
Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the ...
Evotec Enters Master Service Agreement with Kazia Therapeutics contractpharma
April 20, 2021
Evotec SE has entered into a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company.
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB prnasia
March 02, 2021
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM).
Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG prnasia
December 10, 2020
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to launch a clinical trial of multiple therapies..
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study prnasia
April 07, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference En-CPhI.CN
November 26, 2019
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in ...